Seeking Alpha

Zalicus (ZLCS) continues its upward trajectory from yesterday, gaining another 3% on the back...

Zalicus (ZLCS) continues its upward trajectory from yesterday, gaining another 3% on the back yesterday's +15% run after saying it's initiated the second of two Phase 2a clinical studies with Z160, its treatment for chronic neuropathic pain.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)